Effectiveness of a nation-wide COVID-19 vaccination program in Mexico
Authors:
- Omar Yaxmehen Bello-ChavollaOBOmar Yaxmehen Bello-Chavolla
- Neftali Eduardo Antonio-VillaNANeftali Eduardo Antonio-Villa
- Sergio Iván Valdés-FerrerSVSergio Iván Valdés-Ferrer
- Carlos A. Fermín-MartínezCFCarlos A. Fermín-Martínez
- Luisa Fernández-ChirinoLFLuisa Fernández-Chirino
- Daniel Ramírez-GarcíaDRDaniel Ramírez-García
- Javier Mancilla-GalindoJavier Mancilla-Galindo
- Ashuin Kammar-GarcíaAshuin Kammar-García
- José Alberto Ávila-FunesJÁJosé Alberto Ávila-Funes
- Miguel García-GrimshawMGMiguel García-Grimshaw
- Santa Elizabeth Ceballos-LiceagaSCSanta Elizabeth Ceballos-Liceaga
Preprint
Abstract
BACKGROUND: Vaccination has been effective in ameliorating the impact of COVID-19. However, estimation of vaccine effectiveness (VE) is still unavailable for some widely used vaccines and underrepresented groups. Here, we report on the effectiveness of a nation-wide COVID-19 vaccination program in Mexico. METHODS: We used a test-negative design within a national COVID-19 surveillance system to assess VE of the BNT162b2, mRNA-12732, Gam-COVID-Vac, Ad5-nCoV, Ad26.COV2.S, ChAdOx1 and CoronaVac vaccines, against SARS-CoV-2 infection, COVID-19 related hospitalization and death for adults ≥18 years in Mexico. VE was estimated using Cox proportional hazard models considering time-varying vaccination status in partial and fully vaccinated individuals compared to unvaccinated adults, adjusted by age, sex, comorbidities and municipality. We also estimated VE for adults ≥60 years, for cases with diabetes and comparing periods with predominance of variants B.1.1.519 and B.1.617.2. RESULTS: We assessed 793,487 vaccinated compared to 4,792,338 unvaccinated adults between December 24 th , 2020, and September 27 th , 2021. VE against SARS-CoV-2 infection was highest for fully vaccinated individuals with mRNA-12732 (91.5%, 95%CI 90.3-92.4) and Ad26.COV2.S (82.2%, 95%CI 81.4-82.9), whereas for COVID-19 related hospitalization were BNT162b2 (84.3%, 95%CI 83.6-84.9) and Gam-COVID-Vac (81.4% 95%CI 79.5-83.1) and for mortality BNT162b2 (89.8%, 95%CI 89.2-90.2) and mRNA-12732 (93.5%, 95%CI 86.0-97.0). VE for all evaluated vaccines was reduced for adults ≥60 years, people with diabetes, and in periods of Delta variant predominance. CONCLUSIONS: All evaluated vaccines were effective against SARS-CoV-2 infection and COVID-19 related hospitalization and death. Mass vaccination campaigns with multiple vaccine products are feasible and effective to maximize vaccination coverage.Keywords
This publication has 39 references indexed in Scilit:
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineNew England Journal of Medicine, 2021
- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in RussiaThe Lancet, 2021
- COVID-19 Vaccine: Promoting Vaccine AcceptanceAnnals of Internal Medicine, 2021
- The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United StatesClinical Infectious Diseases, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Profiling Cases With Nonrespiratory Symptoms and Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Mexico CityClinical Infectious Diseases, 2020
- Unequal Impact of Structural Health Determinants and Comorbidity on COVID-19 Severity and Lethality in Older Mexican Adults: Considerations Beyond Chronological AgingThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2020
- Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in MexicoThe Journal of Clinical Endocrinology & Metabolism, 2020
- Epidemiology of diabetes mellitus in MexicoNutrition Reviews, 2017